×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Charles Schwab Investment Management Inc. Acquires 13826 Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC)
Defense World
Read Charles Schwab Investment Management Inc. Acquires 13826 Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) at Defense World.
12 hours ago
Does Revance Therapeutics, Inc.'s (NASDAQ:RVNC) CEO Pay Compare Well With Peers?
Yahoo Movies UK
Dan Browne became the CEO of Revance Therapeutics, Inc. (NASDAQ:RVNC) in 2002. First, this article will compare CEO...
5 days ago
Botox rival Revance loses bid to dismiss Allergan trade secrets lawsuit
Reuters
A federal judge on Wednesday said Botox maker AbbVie's Allergan unit can move ahead with its lawsuit accusing Revance Therapeutics of taking...
4 months ago
Principal Financial Group Inc. Sells 693,311 Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC)
MarketBeat
Principal Financial Group Inc. cut its holdings in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC - Free Report) by 72.0% in the fourth...
1 day ago
Revance Q1 DAXXIFY sales up 7%, William Blair bullish on stock By Investing.com
Investing.com
On Monday, William Blair maintained an Outperform rating on Revance Therapeutics (NASDAQ:RVNC) stock, following the company's disclosure of...
3 weeks ago
Revance Therapeutics Shares Rise on CEO's Latest Stock Purchase
MarketWatch
By Sabela Ojea Shares of Revance Therapeutics rose 4.8% to $6.30 in post-market trading after the company said its chief executive bought...
2 months ago
Botox maker's lawsuit against Nashville competitor continues | Health Care | nashvillepost.com
Nashville Post
Allergan alleges former employees brought trade secrets to Revance.
4 months ago
Revance Therapeutics, Inc. (NASDAQ:RVNC) Holdings Decreased by Principal Financial Group Inc.
Defense World
Read Revance Therapeutics, Inc. (NASDAQ:RVNC) Holdings Decreased by Principal Financial Group Inc. at Defense World.
1 day ago
Revance Therapeutics, Inc. (RVNC) Reports Q1 Loss, Lags Revenue Estimates
Yahoo Finance
Revance Therapeutics (RVNC) delivered earnings and revenue surprises of 18.18% and 6.66%, respectively, for the quarter ended March 2024.
3 weeks ago
Trexquant Investment LP Takes $578000 Position in Revance Therapeutics, Inc. (NASDAQ:RVNC)
Defense World
Read Trexquant Investment LP Takes $578000 Position in Revance Therapeutics, Inc. (NASDAQ:RVNC) at Defense World.
1 day ago